The NT-proBNP levels were significantly reduced in both CTD-PAH as well as IPAH/HPAH subgroups at 12 weeks of treatment, but the effect was more pronounced in the CTD-PAH subgroup. This evidence concerns the gene NPPB and idiopathic pulmonary arterial hypertension.